Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine
Authors:
- C. DeenCDC. Deen
- W.J.A. BoersmaWBW.J.A. Boersma
- P.H. PouwelsPPP.H. Pouwels
- F.M. KlisFKF.M. Klis
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Anti-preS2 neutralizes the hepatitis B virus variant with a vaccine-escape mutation at the amino acid position 126 or 145 within the S geneInternational Hepatology Communications, 1994
- Treatment of Clostridium difficile diarrhoea with brewer's yeastThe Lancet, 1994
- New strategies for using mucosal vaccination to achieve more effective immunizationVaccine, 1994
- Induction and Assessment of Immunity at Enteromucosal Surfaces in Humans: Implications for Vaccine DevelopmentClinical Infectious Diseases, 1993
- Saccharomyces boulardii'. A Review of an Innovative Biotherapeutic AgentMicrobial Ecology in Health and Disease, 1993
- The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surfaceJournal of General Virology, 1992
- Improved method for high efficiency transformation of intact yeast cellsNucleic Acids Research, 1992
- Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody responseVirus Research, 1992
- High-copy-number integration into the ribosomal DNA of Saccharomyces cerevisiae: a new vector for high-level expressionGene, 1989
- New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sitesGene, 1988